Celldex Therapeutics, Inc. (CLDX) income statement
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$27.55−0.49 (-1.75%)
Close on Nov 18, 2026Market cap $2.16BP/E –Yield –
Celldex Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 851.3%
- Operating margin
- -206220.3%
- Net margin
- -190220.9%
- Return on equity, FY2025
- -40.6%
Financial strength
- Current ratio
- 11.82
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 77.4%
Valuation
- P/E ratio
- –
- Price to sales
- 13693.00
- Price to book
- 3.03
- Dividend yield
- –
See a number that looks wrong?